Spots Global Cancer Trial Database for aromatase inhibition therapy

Every month we try and update this database with for aromatase inhibition therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer	NCT00005970	Breast Adenocar... HER2 Positive B... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea...	Aromatase Inhib... Cyclophosphamid... Doxorubicin Hyd... Laboratory Biom... Paclitaxel Tamoxifen Citra... Trastuzumab	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer	NCT00629278	Breast Cancer	trastuzumab aromatase inhib... cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel releasing hormo... tamoxifen citra... adjuvant therap... radiation thera...	18 Years - 75 Years	National Cancer Institute (NCI)
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)	NCT00499083	Breast Cancer	therapeutic aut... aromatase inhib... cyclophosphamid... doxorubicin hyd... paclitaxel tamoxifen citra... gene expression... protein express... reverse transcr... immunoenzyme te... immunohistochem... laboratory biom... adjuvant therap... biopsy conventional su... neoadjuvant the... radiation thera...	19 Years - 120 Years	University of Nebraska
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer	NCT00119262	Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea...	doxorubicin hyd... cyclophosphamid... bevacizumab paclitaxel filgrastim pegfilgrastim radiation thera... tamoxifen citra... aromatase inhib...	18 Years -	National Cancer Institute (NCI)
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer	NCT00119262	Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea...	doxorubicin hyd... cyclophosphamid... bevacizumab paclitaxel filgrastim pegfilgrastim radiation thera... tamoxifen citra... aromatase inhib...	18 Years -	National Cancer Institute (NCI)
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer	NCT02003209	HER2-Positive B... Hormone Recepto... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	Aromatase Inhib... Carboplatin Cytology Specim... Docetaxel Goserelin Aceta... Laboratory Biom... Pertuzumab Quality-of-Life... Therapeutic Con... Trastuzumab Whole Breast Ir...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: